Home » Stocks » PRLD

Prelude Therapeutics, Inc. (PRLD)

Stock Price: $41.61 USD 0.81 (1.99%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 1.89B
Revenue (ttm) n/a
Net Income (ttm) -56.93M
Shares Out 35.49M
EPS (ttm) -4.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $41.61
Previous Close $40.80
Change ($) 0.81
Change (%) 1.99%
Day's Open 40.77
Day's Range 39.75 - 42.44
Day's Volume 195,499
52-Week Range 23.69 - 95.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Prelude Therapeutics (PRLD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

2 weeks ago - Zacks Investment Research

WILMINGTON, Del., March 03, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that m...

2 months ago - GlobeNewsWire

WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closin...

3 months ago - GlobeNewsWire

WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology ...

4 months ago - GlobeNewsWire

WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it ha...

4 months ago - GlobeNewsWire

- Completed I nitial P ublic O ffering of C ommon S tock, R aising G ross P roceeds of ~$ 181.9M -

5 months ago - GlobeNewsWire

WILMINGTON, Del., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the first patient has been dosed ...

7 months ago - GlobeNewsWire

WILMINGTON, Del., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its initial public of...

7 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week

Other stocks mentioned: AMST, BSY, CRSR, FCACU, GDRX, GLSI, GRAY ...
7 months ago - Seeking Alpha

WILMINGTON, Del., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its initial public of...

7 months ago - GlobeNewsWire

Prelude Therapeutics has filed to raise $150 million in a U.S. IPO.

7 months ago - Seeking Alpha

About PRLD

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is al... [Read more...]

Industry
Biotechnology
IPO Date
Sep 25, 2020
Stock Exchange
NASDAQ
Ticker Symbol
PRLD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PRLD stock is "Hold." The 12-month stock price forecast is 62.40, which is an increase of 49.96% from the latest price.

Price Target
$62.40
(49.96% upside)
Analyst Consensus: Hold